For: | Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337 [PMID: 35317174 DOI: 10.4254/wjh.v14.i2.319] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v14/i2/319.htm |
Number | Citing Articles |
1 |
Alireza Beheshti Maal, Mohammad Amin Shahrbaf, Bahareh Sadri, Nikoo Hossein-Khannazer, Mohammad Ali Mansournia, Massoud Vosough. Prevalence of Hepatobiliary Manifestations in Inflammatory Bowel Disease: A GRADE Assessed Systematic Review and Meta-Analysis of more than 1.7 Million Patients. Journal of Crohn's and Colitis 2024; 18(3): 360 doi: 10.1093/ecco-jcc/jjad157
|
2 |
Roberto Catanzaro, Francesco Marotta, Azam Yazdani, Morena Sciuto. Inflammatory Bowel Disease Therapies and Acute Liver Injury. Toxics 2024; 12(6): 421 doi: 10.3390/toxics12060421
|
3 |
Paul‐Henry Koop, Constanze Schwenzer, Jan Clusmann, Mara S. Vell, Julius Jaeger, Wenfang Gui, Christian Trautwein, Alexander Koch, Tony Bruns, Carolin V. Schneider, Kai Markus Schneider. Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐Study. Liver International 2024; 44(8): 2038 doi: 10.1111/liv.15945
|
4 |
Pilar Navarro, Lucía Gutiérrez-Ramírez, Antonio Tejera-Muñoz, Ángel Arias, Alfredo J. Lucendo. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease. Nutrients 2023; 15(21): 4507 doi: 10.3390/nu15214507
|
5 |
Javier Pérez-Valenzuela, Lorena Castro Solari, Rodrigo Quera, Luis Contreras . Mesalamine induced hepatotoxicity. Is mesalamine safe?. Revista Española de Enfermedades Digestivas 2024; doi: 10.17235/reed.2024.10131/2023
|